Phase I Clinical Trial of Tremelimumab Plus MEDI3617 in Patients With Unresectable Stage III or Stage IV Melanoma

Trial Profile

Phase I Clinical Trial of Tremelimumab Plus MEDI3617 in Patients With Unresectable Stage III or Stage IV Melanoma

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 24 Jul 2017

At a glance

  • Drugs MEDI 3617 (Primary) ; Tremelimumab (Primary)
  • Indications Malignant melanoma
  • Focus Adverse reactions
  • Most Recent Events

    • 20 Jul 2017 Planned primary completion date changed from 1 Jun 2017 to 1 Jul 2018.
    • 20 Jul 2017 Planned primary completion date changed from 1 Jun 2017 to 1 Jul 2018.
    • 20 Jul 2017 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top